CLINICAL_TRIALS
trial_result
· 2017-03-14
Clinical Trial Update: Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) [Phase 2]
Summary
A Phase 2 trial of dasatinib in combination with the SMO antagonist BMS-833923 for leukemia was terminated, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2017-03-14